— Know what they know.
Not Investment Advice

NPHC OTC

Nutra Pharma Corp.
1W: +0.0% 1M: +0.0% 3M: -66.7% YTD: -66.7% 1Y: +0.0% 3Y: -66.7% 5Y: -93.3%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 52 · $715973 mcap · 7.09B float · 0.0094% daily turnover · Short 36% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.7M
52W Range0.0001-0.005
Volume100,000
Avg Volume665,492
Beta-2.77
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOMichael D. Flax
Employees6
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2001-12-06
6400 Park of Commerce Blvd
Boca Raton, FL 33487
US
954 509 0911
About Nutra Pharma Corp.

Nutra Pharma Corp. (NPHC) operates as a biopharmaceutical firm specializing in obtaining, licensing, and bringing to market a variety of pharmaceutical products, cutting-edge technologies, and both homeopathic and ethical medications. The company primarily targets the U.S. market, focusing its efforts on managing conditions such as pain, neurological ailments, cancer, autoimmune diseases, and infectious diseases. Its current commercial offerings include: Nyloxin and Nyloxin Extra Strength: These products are distributed as an oral spray for alleviating lower back pain, migraines, neck and shoulder discomfort, cramps, and neuropathic pain, and as a topical gel to relieve joint pain, arthritis, and repetitive stress injuries. Pet Pain-Away: An over-the-counter (OTC) homeopathic, non-narcotic, and non-addictive solution for chronic pain in household pets. Luxury Feet: An OTC pain reliever and anti-inflammatory designed to ease foot pain or discomfort specifically caused by high heels and stilettos. Nyloxin Military Strength: A specialized formulation for pain relief aimed at the United States Military and Veteran's Administration. Equine Pain-Away: An OTC topical pain management product for horses. Beyond its existing portfolio, Nutra Pharma Corp. is also advancing several pipeline candidates: RPI-78M: In development to treat neurological conditions such as multiple sclerosis, adrenomyeloneuropathy, and amyotrophic lateral sclerosis, alongside autoimmune diseases like rheumatoid arthritis and myasthenia gravis. RPI-MN: Under investigation for viral diseases, including human immunodeficiency virus (HIV/AIDS) and herpes, as well as for general antiviral applications. RPI-78: Being developed for applications in pain and arthritis. RPI-70: Also in development for pain relief. Founded in 2000, the company is headquartered in Plantation, Florida.

Recent Insider Trades

NameTypeSharesPriceDate
DEITSCH RIK J G-Gift 12,000,000 — 2026-08-21
Pure Raw Supplies, L 0 — 2026-08-21
DEITSCH RIK J 0 — 2021-11-15
DEITSCH RIK J A-Award 3,000,000 — 2017-10-30
DEITSCH RIK J P-Purchase 15,000,000 $0.01 2016-12-19

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms